Genmab plans to present full results at an upcoming medical meeting.

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) ...

Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its ...

—This large, population-based study of patients with PP-DLBCL assessed prognostic factors and confirmed that certain common therapeutic interventions can modify disease progression. Being age 65 years ...

The MarketWatch News Department was not involved in the creation of this content. -- This marks the first provincial listing of Polivy as a first-line treatment for DLBCL in Canada, highlighting Roche ...

Atezolizumab combined with R-GemOx shows favorable safety and efficacy in relapsed/refractory DLBCL, especially in transformed FL cases. The study reported a 59% overall response rate and a 33% ...

—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...

Mohamad Ali Najia, PhD, bioengineer and stem cell biologist, has been awarded a fellowship for early career scientists to research how the legacy of humans’ ancient battles with viruses may play a ...

NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE ® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific ...